REDHILL BIOPHAR/S (NASDAQ:RDHL) PT Set at $23.00 by Ascendiant Capital Markets

Ascendiant Capital Markets set a $23.00 target price on REDHILL BIOPHAR/S (NASDAQ:RDHL) in a report published on Monday morning, Stock Target Advisor reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other analysts have also commented on RDHL. ValuEngine lowered Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. WBB Securities raised REDHILL BIOPHAR/S from a speculative buy rating to a buy rating and set a $17.00 price target on the stock in a research note on Tuesday, March 12th. Finally, Zacks Investment Research lowered Zynerba Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, May 11th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. REDHILL BIOPHAR/S has an average rating of Buy and a consensus target price of $17.75.

Shares of RDHL stock opened at $6.64 on Monday. The company’s 50-day moving average price is $7.05. REDHILL BIOPHAR/S has a 12 month low of $5.13 and a 12 month high of $11.49. The firm has a market capitalization of $147.99 million, a price-to-earnings ratio of -3.91 and a beta of 1.40. The company has a quick ratio of 3.99, a current ratio of 4.09 and a debt-to-equity ratio of 0.06.

REDHILL BIOPHAR/S (NASDAQ:RDHL) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.35) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.04. REDHILL BIOPHAR/S had a negative return on equity of 97.62% and a negative net margin of 506.47%. The firm had revenue of $1.74 million for the quarter, compared to analyst estimates of $2.98 million. As a group, analysts forecast that REDHILL BIOPHAR/S will post -1.3 EPS for the current year.

Several institutional investors have recently bought and sold shares of RDHL. Van ECK Associates Corp lifted its stake in shares of REDHILL BIOPHAR/S by 42.1% in the fourth quarter. Van ECK Associates Corp now owns 10,787 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 3,195 shares during the period. Geode Capital Management LLC acquired a new position in shares of REDHILL BIOPHAR/S in the fourth quarter worth approximately $73,000. D. E. Shaw & Co. Inc. acquired a new position in shares of REDHILL BIOPHAR/S in the fourth quarter worth approximately $186,000. Sanders Morris Harris LLC acquired a new position in shares of REDHILL BIOPHAR/S in the second quarter worth approximately $330,000. Finally, Menta Capital LLC lifted its stake in shares of REDHILL BIOPHAR/S by 9.4% in the fourth quarter. Menta Capital LLC now owns 93,872 shares of the biotechnology company’s stock worth $521,000 after acquiring an additional 8,087 shares during the period. 35.48% of the stock is currently owned by institutional investors.

REDHILL BIOPHAR/S Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.

Featured Article: Cost of Equity

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.